84.86

1.78% -1.54

After Hours: 85.90 1.04 +1.23%

Guardant Health Inc (GH)

Overview News Price History Option Chain Financials Why GH Down? Discussions Forecast

Guardant Health Inc stock is traded at $84.86, with a volume of 1.48M. It is down -1.78% in the last 24 hours and down -0.74% over the past month. Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Previous Close:

$86.40

Open:

$86.67

24h Volume:

1.48M

Relative Volume:

0.74

Market Cap:

$11.13B

Revenue:

$982.02M

Net Income/Loss:

$-416.28M

P/E Ratio:

-25.60

EPS:

-3.3148

Net Cash Flow:

$-233.07M

1W Performance:

-8.60%

1M Performance:

-0.74%

6M Performance:

+32.20%

1Y Performance:

+89.21%

1-Day Range:

$84.32

$88.20

1-Week Range:

$74.55

$92.40

52-Week Range:

$36.36

$120.74

Guardant Health Inc Stock (GH) Company Profile

Name

Guardant Health Inc

Sector

Healthcare (1112)

Industry

Diagnostics & Research (52)

Phone

855-698-8887

Address

3100 HANOVER STREET, PALO ALTO

Employee

2,506

Twitter

@guardanthealth

Next Earnings Date

2026-02-19

Latest SEC Filings

GH's Discussions on Twitter

Compare GH vs TMO, DHR, IDXX, A, WAT

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GH Guardant Health Inc	84.86	11.33B	982.02M	-416.28M	-233.07M	-3.3148
TMO Thermo Fisher Scientific Inc	531.67	195.93B	44.56B	6.72B	6.29B	17.74
DHR Danaher Corp	198.14	140.56B	24.57B	3.60B	5.26B	5.051
IDXX Idexx Laboratories Inc	580.76	46.39B	4.30B	1.06B	1.04B	13.08
A Agilent Technologies Inc	119.77	34.02B	7.07B	1.29B	993.00M	4.5355
WAT Waters Corp	326.20	32.49B	3.17B	642.63M	516.49M	10.77

Guardant Health Inc Stock (GH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-20-26	Reiterated	Canaccord Genuity	Buy
Feb-17-26	Initiated	Robert W. Baird	Outperform
Jan-05-26	Downgrade	Evercore ISI	Outperform → In-line
Dec-02-25	Resumed	Morgan Stanley	Overweight
Sep-25-25	Upgrade	Wolfe Research	Peer Perform → Outperform
Sep-22-25	Resumed	Wells Fargo	Overweight
Apr-10-25	Initiated	Mizuho	Outperform
Jan-23-25	Initiated	Barclays	Overweight
Jun-28-24	Upgrade	Guggenheim	Neutral → Buy
Jun-03-24	Resumed	Jefferies	Buy
Apr-24-24	Resumed	Craig Hallum	Buy
Dec-14-23	Initiated	Guggenheim	Neutral
Dec-13-23	Initiated	Wolfe Research	Peer Perform
Nov-13-23	Upgrade	Raymond James	Mkt Perform → Outperform
Sep-28-23	Initiated	Bernstein	Outperform
Sep-27-23	Upgrade	Piper Sandler	Neutral → Overweight
Jul-05-23	Resumed	JP Morgan	Overweight
May-26-23	Upgrade	Citigroup	Neutral → Buy
May-05-23	Initiated	UBS	Buy
Mar-09-23	Downgrade	Citigroup	Buy → Neutral
Jan-05-23	Initiated	Scotiabank	Sector Outperform
Nov-01-22	Downgrade	Piper Sandler	Overweight → Neutral
Oct-19-22	Initiated	Craig Hallum	Buy
Oct-06-22	Initiated	Stephens	Overweight
Aug-25-22	Initiated	Credit Suisse	Outperform
Jun-03-22	Initiated	Piper Sandler	Overweight
Apr-28-22	Resumed	BTIG Research	Buy
Feb-24-22	Reiterated	Canaccord Genuity	Buy
Feb-24-22	Reiterated	Citigroup	Buy
Feb-24-22	Reiterated	Cowen	Outperform
Feb-24-22	Reiterated	Morgan Stanley	Overweight
Feb-24-22	Reiterated	SVB Leerink	Outperform
Feb-24-22	Reiterated	Stifel	Buy
Feb-24-22	Reiterated	Wells Fargo	Overweight
Oct-15-21	Resumed	Cowen	Outperform
Jun-15-21	Initiated	Raymond James	Mkt Perform
Jun-03-21	Initiated	Goldman	Buy
May-25-21	Initiated	Wells Fargo	Overweight
Jan-11-21	Initiated	Stifel	Buy
Sep-09-20	Initiated	Morgan Stanley	Overweight
Jun-12-20	Initiated	BTIG Research	Buy
Feb-21-20	Initiated	Guggenheim	Buy
Jan-07-20	Initiated	Citigroup	Buy
Aug-07-19	Reiterated	Canaccord Genuity	Buy
Apr-16-19	Initiated	Canaccord Genuity	Buy
Apr-10-19	Upgrade	BofA/Merrill	Neutral → Buy
Feb-28-19	Reiterated	BofA/Merrill	Neutral
Oct-29-18	Initiated	BofA/Merrill	Neutral
Oct-29-18	Initiated	JP Morgan	Overweight
Oct-29-18	Initiated	William Blair	Outperform

View All

Guardant Health Inc Stock (GH) Latest News

Apr 14, 2026

Barclays Maintains Guardant Health(GH.US) With Buy Rating, Cuts Target Price to $115 - Moomoo

Apr 14, 2026

Apr 13, 2026

Mizuho Securities Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $135 - Moomoo

Apr 13, 2026

TD Cowen cuts Guardant Health stock price target on valuation By Investing.com - Investing.com Canada

Apr 13, 2026

Apr 12, 2026

Cloudflare, ServiceNow, And Guardant Health Are Among Top 10 Large-Cap Losers Last Week (April 6-April 10 - Benzinga

Apr 12, 2026

Apr 11, 2026

Oscar, Guardant, Redwire, Gap, AFLAC: Insider Moves Shock Wall Street - TipRanks

Apr 11, 2026

Apr 10, 2026

Guardant Health Surges to $510 Million in Trading Volume as Insiders and Institutional Investors Dispute Over $81 Share Price - Bitget

Apr 10, 2026

(GH) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily

Apr 10, 2026

GH Stock Price, Quote & Chart | GUARDANT HEALTH INC (NASDAQ:GH) - ChartMill

Apr 10, 2026

Guardant Health real-world data supports Japan approval of ENHERTU for HER2-positive tumors - MSN

Apr 10, 2026

Apr 09, 2026

Guardant Health (GH) partners with Manulife to launch Shield multi-cancer detection test in Asia - MSN

Apr 09, 2026